Management of Thrombocytopenia in Cancer Patients.
Cancer Treat Res
; 179: 139-150, 2019.
Article
em En
| MEDLINE
| ID: mdl-31317485
ABSTRACT
Chemotherapy-induced thrombocytopenia (CIT) is a frequent complication of cancer therapy, leading to increased risk of bleeding, when the thrombocytopenia is severe (<10,000/mcL). However, the major clinical relevance of CIT is the subsequent delay or dose reduction in chemotherapy. CIT, therefore, leads to reduced relative dose intensity (RDI) of cancer therapy. Reduced RDI has been shown in several studies to impact progression-free survival and other cancer outcomes. While there are a number of factors leading to reduced RDI, CIT is a common cause. We review the causes and clinical manifestations of CIT, the current recommendations for management, and the status of research to develop targeted therapies to treat CIT.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Trombocitopenia
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
/
Guideline
/
Observational_studies
Limite:
Humans
Idioma:
En
Revista:
Cancer Treat Res
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos